**TBRNG-xxx**

**Gut Microbiota-Mediated Pharmacokinetic Drug-Drug Interactions between Mycophenolic Acid and Trimethoprim-Sulfamethoxazole in Humans**

**Dukaew N1,2, Thongkumkoon P3, Sirikaew N3, Dissook S, Sakuludomkan W, Tongjai S, Thiennimitr P, Na Takuathung M, Benjanuwattra J, Kongthaweelert P, Koonrungsesomboon N.**

1 Department of Pharmacology, Faculty of Medicine, Chiang Mai University, 110 Intawaroros

 Road, Sriphoom, Muang, Chiang Mai 50200, Thailand.

2 Clinical Research Center for Food and Herbal Product Trials and Development (CR-FAH),

 Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

3 Center of Multidisciplinary Technology for Advanced Medicine (CMUTEAM), Faculty of

 Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

**Email: xxxx@xxx.xx.xx**

**ABSTRACT**

Mycophenolic acid (MPA) and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly prescribed together in certain groups of patients, including solid organ transplant recipients. However………………………

This research was supported by ………

**Keywords:** drug-drug interaction; gut microbiota; mycophenolate mofetil; mycophenolic acid; pharmacokinetics; trimethoprim-sulfamethoxazole.

**INTRODUCTION**

The introduction should be as concise as possible, without subheadings. It introduction should provide an adequate background, the importance and the objectives of the work.

Interleukin-2 is a potent growth factor produced by activated T cells and stimulates a number of immune cells [1, 2]. It also enhances ……………

**MATERIALS AND METHODS**

*Subheading 1*

Description.

*Subheading 2*

Description.

*Subheading 3*

Description.

**RESULTS**

*Subheading 1*

Description. As illustrated in **Fig. 1A**, expression levels of drug transporters in wild type cell line were greater than that of mutant cell line, and these correlated with drug susceptibility profiles of the cell lines (**Fig. 1B and 1C**), the IC50 values of each drug were shown in **Table 1**.

 According to previous studies, the …

****

**Figure 1** Figure title. Figure descriptions……..

*Subheading 2*

Description. The results are shown in Table 1.

**Table 1** The table title**.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

a Footnotes should be written in Times New Roman, 12 points, regular, justified to both sides,

 and placed below the table.

*Subheading 3*

Description.

**DISCUSSION AND CONCLUSION**

Discussion is for interpretation of the results. Discuss principles and relationship. Point out exception. Show agreement/disagreement with published research work. A combined Results and Discussion section is often appropriate.

Conclusion is to describe the conductions and/or the significance of the work.

**ACKNOWLEDGEMMENTS**

Provide the names of those who have providing help during the research (including funding agencies).

**REFERENCES**

1. Enderby, C., Keller, C.A. An overview of immunosuppression in solid organ transplantation. Am. J. Manag. Care. 2015;21:12-23.
2. Ritter, M.L.; Pirofski, L. Mycophenolate mofetil: Effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl. Infect. Dis. 2009;11:290-297.
3. Mok, C.C.; Tse, S.M.; Chan, K.L.; Ho, L.Y. Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: A propensity score analysis of a longitudinal cohort. Lupus. 2018;27:722-727.
4. Davulcu, E.A.; Vural, F. Immunosuppressive agents in hematopoietic stem cell transplantation. Trends Transplant.2017;10:1-3.

**GENERAL FORMATTING:**

**File format:** Microsoft Word (.docx) only

**Save as >> Save as type: " Word Document (\*.docx)"**

**Paper size:** A4 ("8.27 x 11.69 in" or "210 x 297 mm")

**Page layout:** Portrait, single column.

**Margins:** 1 inch (2.54 cm) at all sides.

**Font: Times New Roman.**

**Line spacing: 1.0 (single-spaced; spacing before = 0 pt, after = 0 pt)**

**throughout the text.**

**Title: Sentence case. 14-point (bold text).**

**Authors: 12-point (bold text).**

The presenting author should be underlined.

Give an asterisk (\*) to the corresponding author.

**Affiliations:** 12-point (regular text).

**Heading:** *e.g.,* ABSTRACT, INTRODUCTION, RESULTS, *etc.*

**CAPITAL LETTER, 12-point (bold text).**

*Do not leave a line between the headings and the following text.*

**Abstract body:** 12-point (regular text). Do not exceed **250 words.**

**Text body:** 12-point (regular text).

**Paragraph:** Start with indentation (1 in.) and *Justify to both sides.*

**Abbreviations:** Spelled out, in parenthesis, in the first use in the text.

**Unit:** SI system.

**References:** **Vancouver style.** In addition, **please be sure to check the format of**

**in-line reference as follow:** indicate references by number(s) in square brackets in the order of their appearance in the text and in line with text **(e.g.** some text … **[1]**, some text … **[2,4],** etc.**).**

**PROCEEDING GUIDELINES:**

All Proceedings must be **written in ENGLISH (either American English or British English, but not a mixture of these)**. Graphs, figures, and tables are not allowed.

The proceeding file must contain TITLE, AUTHORS, AFFILIATIONS, ABSTRACT, KEYWORDS (3 - 6 keywords), INTRODUCTION, MATERIALS AND METHODS, RESULTS, DISCUSSION AND CONCLUSION, and REFERENCES.

Indicate **Presenting Author** with **Underline**

Indicate the **Corresponding Author** with an **Asterisk (\*)** after the name.

FIGURES and TABLES must be INCLUDED in the MANUSCRIPT.

Standard abbreviations can be used throughout. Any special or unusual abbreviations should be spelled out in full at first mention, followed by the abbreviation in parentheses. It is recommended that you use abbreviations minimally in your abstract.

**Greek characters** (*e.g.,* alpha, beta) in both the title and the text **should be spelled out**.

Total number of pages should be 4 - 8 pages.

Please remember that the research work to be submitted for Proceeding Publication must contain any bioinformatic analysis of omics data.

Check carefully for any misspellings and/or typographical errors.

**When filling out the online submission form, if symbol characters are used, please try copying and pasting such characters from your document file (e.g., Microsoft Word).**

**Once your proceeding is ACCEPTED, an EXTRA 1,000 BAHT will be CHARGED to the REGISTRANT for FULL PAPER PUBLICATION (ISBN: xxx-xxx-xxx-x).**

**ACCEPTED PROCEEDING must also be presented as a POSTER** unless it is selected as an oral.